¼¼°èÀÇ ¾àÁ¦ ÄÚÆÃ Ç³¼± Ä«Å×ÅÍ ½ÃÀå
Drug-Coated Balloon Catheters
»óǰÄÚµå : 1780711
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 375 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¾àÁ¦ ÄÚÆÃ Ç³¼± Ä«Å×ÅÍ ½ÃÀåÀº 2030³â±îÁö 21¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 15¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¾àÁ¦ ÄÚÆÃ Ç³¼± Ä«Å×ÅÍ ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 6.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 21¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ PaclitaxelÀº CAGR 4.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 13¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Sirolimus ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 8.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3¾ï 9,580¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ¾àÁ¦ ÄÚÆÃ Ç³¼± Ä«Å×ÅÍ ½ÃÀåÀº 2024³â¿¡ 3¾ï 9,580¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 9.2%¸¦ °ßÀÎÇϸç, 2030³â¿¡´Â 4¾ï 1,490¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.0%¿Í 5.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ' ¾àÁ¦ ÄÚÆÃ Ç³¼± Ä«Å×ÅÍ ' ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¾à¹° ÄÚÆÃ Ç³¼± Ä«Å×ÅͰ¡ ½ÉÇ÷°ü Ä¡·á¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â?

¾à¹° ÄÚÆÃ Ç³¼±(DCB) Ä«Å×ÅÍ´Â ÁßÀçÀû ½ÉÀ庴ÇÐ ¹× Ç÷°ü ¼ö¼úÀÇ ÆÇµµ¸¦ ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ±âÁ¸ ½ºÅÙÆ®¿Í ´Þ¸® DCB´Â Ç÷°üº®¿¡ Á÷Á¢ Ç×Áõ½ÄÁ¦¸¦ ÁÖÀÔÇÏ¿© ¿µ±¸ÀûÀÎ ÀÓÇöõÆ®¸¦ ³²±âÁö ¾Ê°í ÀçÇùÂøÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ÀÌ ÀåÄ¡´Â °ü»óµ¿¸ÆÁúȯ, ¸»Ãʵ¿¸ÆÁúȯ(PAD), ½ºÅÙÆ®³» ÀçÇùÂø¿¡ ƯÈ÷ À¯¿ëÇϸç, ÇÕº´ÁõÀÌ ÀûÀº º¸´Ù ¾ÈÀüÇÑ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

¾î¶² ±â¼ú ¹ßÀüÀÌ DCBÀÇ ¼º´ÉÀ» Çâ»ó½Ã۰í Àִ°¡?

Æú¸®¸Ó°¡ ¾ø´Â ¾à¹° ÄÚÆÃ, Ä£¼ö¼º Àü´Þ ½Ã½ºÅÛ, »ýºÐÇØ¼º ij¸®¾îÀÇ È¹±âÀûÀÎ ¹ßÀüÀ¸·Î Ç¥Àû µ¿¸Æ¿¡¼­ ¾à¹°ÀÇ À¯Áö ¹× Èí¼ö°¡ Çâ»óµÇ¾ú½À´Ï´Ù. ÆÄŬ¸®Å¹¼¿À» ±â¹ÝÀ¸·Î ÇÑ DCB¿Í ½Ç·Î¸®¹«½º¸¦ ÄÚÆÃÇÑ DCBÀÇ °³¹ß·Î ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á È¿°ú¸¦ ´õ ¿À·¡ Áö¼Ó½Ãų ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Ä«Å×ÅÍÀÇ À¯¿¬¼º, ¾à¹°ÀÇ Á¤¹Ð Åõ¿©, ¿µ»ó À¯µµÇÏ Àü°³ µîÀÇ ¹ßÀüÀ¸·Î ½Ã¼úÀÇ ¼º°ú´Â ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

±ÔÁ¦¿Í ½ÃÀå ¼ö¿ä´Â äÅÿ¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

FDA ¹× CE ¸¶Å© ±â°ü°ú °°Àº ±ÔÁ¦±â°üÀº ½ÉÇ÷°ü ÁßÀç¼ú ÀÌ¿ÜÀÇ »õ·Î¿î ÀûÀÀÁõ¿¡ ´ëÇØ DCB¸¦ ½ÂÀÎÇÏ´Â °æÇâÀÌ °­È­µÇ°í ÀÖÀ¸¸ç, ´ç´¢º´¼º Ç÷°ü ÇÕº´Áõ ¹× µ¿Á¤¸Æ·ç Ä¡·á¿¡ ´ëÇÑ »ç¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÃÖ¼Òħ½À ¼ö¼ú ¹× ¿Ü·¡ ¼ö¼ú Áõ°¡´Â ¾àÁ¦¿ëÃâ ½ºÅÙÆ®(DES)¸¦ ´ëüÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀ̰í È¿À²ÀûÀÎ ´ë¾ÈÀ¸·Î DCB¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº?

¾à¹° ÄÚÆÃ Ç³¼± Ä«Å×ÅÍ ½ÃÀåÀÇ ¼ºÀåÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, ½ºÅÙÆ® ¾ø´Â Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ¾à¹°Àü´Þ ÄÚÆÃÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. Àα¸ °í·ÉÈ­, ¿Ü·¡ Ç÷°ü¼ºÇü¼úÀÇ µµÀÔ È®´ë, ½Å¾à Á¦Á¦ÀÇ ÀÓ»ó½ÃÇè ÁøÇà Áß µîµµ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ½ÉÇ÷°ü Ä¡·á¿¡ ´ëÇÑ DCBÀÇ Àû¿ë È®´ë´Â ÀÓ»óÀû ¿¬°ü¼º°ú »ó¾÷Àû °¡´É¼ºÀ» ³ÐÇô°¡°í ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(Paclitaxel, Sirolimus); Á¦Ç°(°ü»óµ¿¸Æ Áúȯ, ¸»ÃÊÇ÷°ü Áúȯ); ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Ŭ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Drug-Coated Balloon Catheters Market to Reach US$2.1 Billion by 2030

The global market for Drug-Coated Balloon Catheters estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Paclitaxel, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Sirolimus segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$395.8 Million While China is Forecast to Grow at 9.2% CAGR

The Drug-Coated Balloon Catheters market in the U.S. is estimated at US$395.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$414.9 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global "Drug-Coated Balloon Catheter" Market - Key Trends & Drivers Summarized

Why Are Drug-Coated Balloon Catheters Gaining Traction in Cardiovascular Care?

Drug-coated balloon (DCB) catheters have become a game-changer in interventional cardiology and vascular surgery. Unlike traditional stents, DCBs deliver antiproliferative drugs directly to vessel walls, reducing the risk of restenosis without leaving a permanent implant. These devices are particularly useful for coronary artery disease, peripheral artery disease (PAD), and in-stent restenosis, offering a safer alternative with fewer complications.

What Technological Advances Are Improving DCB Performance?

Breakthroughs in polymer-free drug coatings, hydrophilic delivery systems, and biodegradable carriers have enhanced drug retention and absorption in target arteries. The development of paclitaxel-based and sirolimus-coated DCBs has led to longer-lasting therapeutic effects with minimal side effects. Advances in catheter flexibility, precision drug dosing, and imaging-guided deployment have further improved procedural outcomes.

How Are Regulations and Market Demand Influencing Adoption?

Regulatory bodies like the FDA and CE Marking agencies are increasingly approving DCBs for new indications beyond cardiovascular interventions, expanding their use in diabetic vascular complications and arteriovenous fistula treatments. The rise in minimally invasive surgeries and outpatient procedures has also driven demand for DCBs as a cost-effective and efficient alternative to drug-eluting stents (DES).

What Is Propelling the Market Growth?

The growth in the Drug-Coated Balloon Catheter market is fueled by the rising prevalence of cardiovascular diseases, increasing preference for non-stent-based interventions, and advancements in drug delivery coatings. The aging population, growing adoption of outpatient angioplasty procedures, and ongoing clinical trials for new drug formulations are also key market drivers. Furthermore, the expansion of DCB applications into non-cardiac vascular treatments is broadening their clinical relevance and commercial potential.

SCOPE OF STUDY:

The report analyzes the Drug-Coated Balloon Catheters market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Paclitaxel, Sirolimus); Product (Coronary Artery Disease, Peripheral Vascular Disease); End-Use (Hospital, Clinics, Ambulatory Surgery Centers)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â